Rhythm Pharma

Rhythm Pharmaceuticals Inc. CSO Disposes of Common Stock

Alastair Garfield, Chief Scientific Officer of Rhythm Pharmaceuticals Inc., has reported the disposal of common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice.

Rhythm Pharmaceuticals' Chief Scientific Officer Alastair Garfield Reports Disposal of Common Shares

Rhythm Pharmaceuticals, Inc. insider Alastair Garfield sold 1,319 shares at an average price of $64.81, totaling $85,484.39, resulting in a 29.67% decrease in ownership. Post-sale, he holds 3,126 shares valued at approximately $202,596.06. The transaction was disclosed to the SEC. The stock traded down 1.7% to $65.78, with a market cap of $4.18 billion. The company reported a quarterly EPS of ($0.81), missing estimates, and had a revenue of $37.72 million, up 25.9% year-over-year. Analysts maintain a "Buy" rating with a consensus target price of $77.31.

Rhythm Pharmaceuticals Inc. CSO Disposes of Common Stock

Summary

Impact Analysis